By John Meyer, consultant in financial affairs – Eurasia Business News, December 22, 2025. Article no. 1947

The government has allowed Russian pharmaceutical companies to produce analogues of Ozempik until the end of 2026 without the consent of the foreign copyright holder. The decision was made in order to provide the population with the drug “Semaglutide”.

The Russian government has allowed national pharmaceutical companies PSK Pharma and Promomed Rus to produce analogues of the drug Ozempik until the end of 2026 without the consent of the foreign copyright holder, follows from the Russian government orders published on the official Internet portal of legal information.

“To allow Promomed Rus Limited Liability Company to use inventions protected by Russian patents (RU) <… > owned by Novo Nordisk A/S (DK), until December 31, 2026 inclusive, without the consent of Novo Nordisk A/S (DK),” says the legal document.

PSK Pharma received a similar official permit.

According to the orders, the decision was made to provide Russian patients with a drug with the international non-proprietary name Semaglutide.

Ozempic is an injectable drug from the Danish company Novo Nordisk based on semaglutide, a synthetic analogue of GLP-1. It stimulates the production of insulin, lowers glucose levels and promotes weight loss due to appetite control, which has made the drug popular among those who want to lose weight quickly.

Deliveries of Ozempik to Russia stopped after Russia launched a military operation in Ukraine on February 24, 2022. Until 2023, the medicine was the only drug with semaglutide on the Russian market. In subsequent years, domestic companies established the production of their own drugs based on semaglutide, including injectable Tirzetta, Quincent and Velgia from Promomed.

Read also : Gold : Build Your Wealth and Freedom

According to the analytical company DSM Group, in the first eight months of 2024, 829.9 thousand packages of semaglutide-based drugs were sold in Russia for 4.9 billion rubles, which is several times higher than in the same period in 2023.

The bulk of sales were Russian analogues of Semavik (Geropharm) and Quincent (Promomed), while the original Ozempic of the Danish company Novo Nordisk was sold to a limited extent and mainly for its intended purpose.

Read also : Russia’s economy indicators for 2025 and 2026

Experts attribute the increase in demand to the affordable price and the use of semaglutide for weight loss, as well as the treatment of diabetes mellitus and concomitant diseases. At the same time, experts warn about the possible risks of self-use of the drug, and doctors note that it is prescribed not only by endocrinologists.

Advertisements

Our community already has 190,000 readers, joins us !

Subscribe to our Telegram channel

Follow us on Telegram, Facebook and Twitter

© Copyright 2025 – Eurasia Business News. Article no. 1949